VENTRIPOINT Aktie

 

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Point-of-care infectious disease diagnostics valued at $53 billion in 2024 are projected to nearly double by 2033, driven by AI systems that deliver......

New care delivery model to provide advanced cardiac imaging to remote and Indigenous communities in British Columbia, across Canada, and worldwide. Toronto, Ontario – TheNewswire - December 12, 2025 - Ventripoint Diagnostics Ltd. ("Ventripoint", “VPT” or the "Company"), (TSXV:VPT; OTC:VPTDF) a leader in AI-enhanced cardiac imaging solutions, is proud to announce a transformative partnership with Nisg̱a'a Valley Health Authority (NVHA) that is the next step towards forming a groundbreaking new model for delivering accessible, high-quality heart care powered by artificial intelligence. The new model follows a “hub-and-spoke” design, where a central hub with advanced cardiac capabilities provides support to connected sites in smaller, remote, and Indigenous communities. Local healthcare providers can acquire, enhance and read ultrasound scans using VMS+™ and transmit them digitally as needed to specialists at the hub for rapid interpretation and consultation. The Nisg̱a'a ...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

New CFO appointment strengthens Ventripoint's leadership team and supports global rollout of AI-powered VMS+™ cardiac imaging platform. Toronto, Ontario – TheNewswire - December 3, 2025 - Ventripoint Diagnostics Ltd. ("Ventripoint", “VPT” or the "Company"), (TSXV:VPT; OTC:VPTDF) a leader in AI-enhanced cardiac imaging solutions, today announced the appointment of David Swetlow, CPA, CA, iGP as Chief Financial Officer (“CFO”), effective immediately. This appointment represents an important step in strengthening Ventripoint's leadership team as the Company embarks on its new commercial strategic vision and transitions into its growth phase. Mr. Swetlow brings extensive senior management, financial and public company leadership experience from various roles across high-growth medical technology and innovative life science companies, including Sernova, Ondine, Protox, HealthPricer, One Person Health, QLT and Xillix, with a track record of building and executing robust capital...

Toronto, Ontario--(Newsfile Corp. - November 27, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior ......

  Toronto, Ontario – TheNewswire - November 6, 2025 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation"), (TSXV:VPT) is pleased to announce that it has agreed to settle an aggregate of $542,591.50 of debt owed to certain arm's length creditors of the Corporation by issuing an aggregate of 5,425,915 common shares (the “Shares”) of the Corporation at a price of $0.10 per share.   The Shares are subject to a hold period of four-month and one day. The Corporation determined to satisfy the indebtedness with Shares in order to preserve its cash for development of its business. Issuance of the Shares is subject to approval by the TSX Venture Exchange.   About Ventripoint Diagnostics Ltd.   Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provide...

Study to evaluate potential to reduce cardiac MRI demand and expand access to advanced heart diagnostics across care settings Toronto, Ontario – TheNewswire - October 29, 2025 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) today announced it has entered into a collaboration with Providence Health Care Ventures (“PHC Ventures”) to validate the Company's VMS+™ platform at St. Paul's Hospital in Vancouver, British Columbia. The collaboration will evaluate how artificial intelligence-enhanced echocardiography may reduce dependence on cardiac MRI by providing accurate cardiac measurements earlier in the diagnostic pathway, with the potential for a subset of patients to avoid MRI entirely. Cardiac MRI is widely regarded as the gold standard for accurate heart volume and function measurements, but limited availability and long wait times can delay treatment decisions. VMS+™ uses artificial intelligence to generate 3-D heart models from stand...

  Toronto, Canada — TheNewswire --- October 24, 2025 — Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF), a leading provider of innovative cardiac diagnostic solutions, is pleased to provide a shareholder update.   Dear Shareholders,   We are pleased to provide this update on advancements at Ventripoint and to express our ongoing appreciation for your support. Since our last update the Ventripoint team has continued to build a foundation for commercializing VMS+™ and advancing the company towards growth.  The business plan and budget have been updated and management is currently pursuing sufficient capital to enable proper execution of the plan.   Business Plan   Following the regulatory clearance/approval of the latest version of VMS+™ our attention is now directed towards evolving the user base from research applications to routine clinical adoption.   An important early step is the upgrade of existing sites to VMS+™ V4 to ensure t...

  Toronto, Ontario, October 14, 2025 – TheNewswire - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, TSXV:VPT) announces the issuance of an additional $297,000 of unsecured convertible debenture units (“Units”) of its non-brokered private placement (the “Offering”) (see August 26, 2025, September 3, 2025 and October 3, 2025 press releases), subject to TSXV Venture Exchange (“Exchange”) acceptance. Along with the issuance of $270,000 of Units in the first tranche, the Corporation issued an aggregate of $567,000 of Units pursuant to the Offering, which was an increase from the announced size of the Offering. Each Unit is comprised of one (1) unsecured convertible debenture principal amount of $1,000 (“Debentures”) convertible into common shares (“Common Shares”) of the Corporation, and 9,000 common share purchase warrants (“Warrants”).   The Debentures are convertible into Common Shares of the Corporation at the option of the holder at any time prior to ...

  Toronto, Ontario, October 3, 2025 – TheNewswire - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, TSXV:VPT) announces that it will seek approval of TSX Venture Exchange (“TSXV” or the “Exchange”) to extend its previously announced non-brokered private placement (“Offering”) of unsecured convertible debentures (“Debentures”) to November 2, 2025. (See press releases dated August 26, 2025 and September 3, 2025).   Ventripoint also announces that it will seek approval of the TSXV to increase the size of the Offering from $500,000 to $560,000.     Each Unit is comprised: of one (1) unsecured convertible debenture principal amount of $1,000 (“Debentures”) convertible into common shares (“Common Shares”) of the Corporation; and 9,000 common share purchase warrants (“Warrants”).   The Debentures are convertible into Common Shares of the Corporation at the option of the holder at any time prior to maturity at a conversion price of $0.11 per Common Sha...

  Toronto, Ontario – TheNewswire - (September 19, 2024) - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce the successful completion of its annual audit under the Medical Device Single Audit Program (MDSAP), ISO 13485 Quality Management System, and EU Medical Device Regulation (MDR) requirements by Notified Body. The audit resulted in zero major nonconformities and confirmed Ventripoint Diagnostics Ltd.'s continued compliance with global quality and regulatory standards. This achievement reflects Ventripoint's ongoing commitment to delivering safe, effective, and high-quality medical devices to patients worldwide. It also reinforces the company's strong quality culture and dedication to meeting the evolving regulatory requirements across multiple jurisdictions. The audits addressed: MDSAP (Medical Device Single Audit Process): The MDSAP audit, conducted by a third-party auditing organization, ensures compliance with the m...

  Toronto, Ontario, September 3, 2025 – TheNewswire - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, TSXV:VPT) announces the closing of its previously announced (see press release of August 26, 2025) non-brokered private placement (the “Offering”) of unsecured convertible debenture units (“Units). The Corporation has issued an aggregate of 270 Units representing an aggregate of $270,000.   Each Unit is comprised: of one (1) unsecured convertible debenture principal amount of $1,000 (“Debentures”) convertible into common shares (“Common Shares”) of the Corporation; and 9,000 common share purchase warrants (“Warrants”).   The Debentures are convertible into Common Shares of the Corporation at the option of the holder at any time prior to maturity at a conversion price of $0.11 per Common Share (the “Conversion Price”). Each whole Warrant will entitle the holder thereof to purchase one (1) Common Share at a price of $0.14 until December 31, 2027.   The ...

    Toronto, Ontario – TheNewswire - August 26, 2025 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”), (TSXV:VPT) announces a non-brokered private placement of up to CDN$500,000 (the “Offering”) of unsecured convertible debenture units (“Units”) subject to TSXV Venture Exchange (the “Exchange”) acceptance. Each Unit will be comprised of one (1) unsecured convertible debenture principal amount of $1,000 (“Debentures”) convertible into common shares (“Common Shares”) of the Corporation, and 9,000 common share purchase warrants (“Warrants”). Depending on market conditions, the Corporation may increase the size of the Offering, subject to approval of the Exchange.   The Debentures will be convertible into Common Shares of the Corporation at the option of the holder at any time prior to maturity at a conversion price of $0.11 per Common Share (the “Conversion Price”). Each whole Warrant will entitle the holder thereof to purchase one (1) Common Shar...

  Toronto, Ontario – TheNewswire - August 18, 2025 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”,) (TSXV:VPT; OTC:VPTDF) a leader in AI-powered heart analysis solutions, is pleased to announce the appointment of Thomas Brown, former Vice President of North American Sales at Intelligent Ultrasound, as Director of the Congenital Heart Defect (CHD) Program.   Mr. Brown brings more than 20 years of leadership experience in global medical imaging sales, commercialization, and market expansion. At Intelligent Ultrasound, he drove significant international growth, launching AI-powered imaging solutions into both clinical and training markets.   This appointment is a strategic move to accelerate Ventripoint's market leadership in the congenital heart defect segment - one of the largest and fastest-growing areas in pediatric cardiology - with the potential to expand adoption of VMS+™ into related high-value markets such as cardio-oncology, pulmonary hypertension, heart failur...

  Toronto, Ontario – TheNewswire - August 15, 2025 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”), (TSXV:VPT; OTC:VPTDF) a leader in AI-powered heart analysis solutions, today announced the launch of a targeted marketing program focused on the diagnosis and monitoring of congenital heart defects (CHD). The initiative is designed to solidify Ventripoint's leadership position in this high-need clinical area, while laying the foundation for expansion into other rapidly growing segments including cardio-oncology, pulmonary hypertension, heart failure, and valvular heart disease.   The new program will spotlight the Company's flagship VMS+™ system, which delivers MRI-comparable volumetric and functional cardiac measurements using standard echocardiography. This capability eliminates many of the patient and workflow barriers associated with cardiac MRI - particularly critical for CHD patients, who often require frequent monitoring from infancy through adulthood.   “CHD ...

Toronto, Ontario--(Newsfile Corp. - August 13, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mi......

  Toronto, Ontario – TheNewswire - July 28, 2025 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”), (TSXV:VPT; OTC:VPTDF) is pleased to announce that it has received the first purchase order from Lishman Global Inc. for VMS+ technology to be used within its echocardiography image platform in the People's Republic of China.  Lishman will use the technology within six hybrid echocardiography systems built to support technology demonstration, clinical validation, and regulatory submission to the China Food and Drug Administration (“CFDA”).   Previously, Lishman's Chinese subsidiary had received CFDA approval and a Certificate of Production (CoP) from the CFDA in the People's Republic of China for the VMS+ product used for analysis of the right ventricle (RV) only of the heart. Through the manufacture and sale of a limited number of these systems Lishman was able to develop market insights, validate the market opportunity, identify and engage with channel partners and b...

  Toronto, Ontario – TheNewswire - July 11, 2025 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”), (TSXV:VPT) is pleased to announce that it has signed a non-binding term sheet with Lishman Global Inc. outlining the exclusive , non-transferable license of Ventripoint technology for use within Lishman's echocardiography image platform in the People's Republic of China including the Special Administrative Regions of Hong Kong and Macao (the “Territory”).   Previously, Lishman's Chinese subsidiary had received CFDA approval and a Certificate of Production (CoP) from the CFDA in the People's Republic of China for the VMS+ product used for analysis of the right ventricle (RV) only of the heart. The subsidiary has a GMP certified manufacturing facility in China that is able to produce at a scale capable of addressing the Chinese market.   Upon execution, the new license will enable Lishman and its subsidiaries to fully integrate VMS+ 4.0 within its cart-based and hybri...

  Toronto, Ontario – TheNewswire - June 30, 2025 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, (TSXV:VPT) announces it will satisfy debenture interest payment obligations with the issuance of common shares, subject to TSX Venture Exchange (“TSXV”) approval. The Corporation will issue an aggregate of 564,473 common shares (“Shares”) for the payment of an aggregate of $76,203.59 of interest owing on certain outstanding Convertible Debentures issued by the Corporation on May 10, 2024, September 20, 2024 and December 16, 2024. The Convertible Debentures bear interest at the rate of 10% per annum, payable every 6 months. The Shares will be issued at a deemed price of $0.135, subject to the approval of TSXV and are subject to a hold period of 4 months and one day. The issuance of the Shares will not create a control person of the Corporation.   About Ventripoint Diagnostics Ltd.   Ventripoint has become an industry leader in the application of AI (Artificial Intellig...

  Toronto, Ontario – TheNewswire - June 17, 2025 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce that it has entered into an advisory agreement with Fournel Advisory (“Fournel”) to provide the Company with financial advisory, business development and M&A services for one year to accelerate the commercialization of Ventripoint's AI-powered, heart-scanning technology. Under the terms of the agreement the Company shall pay a cash fee and provide Fournel an option to purchase 265,000 common shares at the market price on June 11, 2025 of $0.11, subject to TSX Venture Exchange approval.   Strategic Advisory   Fournel Advisory is a Paris-based consulting firm dedicated to supporting entrepreneurs and business leaders across Small and Mid-Cap markets. Since 2013, Fournel has specialized in M&A advisory, fundraising, and special situations, both in France and internationally. With a strong focus on the Healthcare ...